Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Enterprise Value (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Enterprise Value data on record, last reported at -$218.5 million in Q3 2025.

  • For Q3 2025, Enterprise Value fell 13.6% year-over-year to -$218.5 million; the TTM value through Sep 2025 reached -$218.5 million, down 13.6%, while the annual FY2024 figure was -$153.8 million, 6.45% down from the prior year.
  • Enterprise Value reached -$218.5 million in Q3 2025 per AMPH's latest filing, down from -$189.9 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$56.4 million in Q1 2021 and bottomed at -$289.6 million in Q1 2024.
  • Average Enterprise Value over 5 years is -$172.6 million, with a median of -$178.8 million recorded in 2023.
  • Peak YoY movement for Enterprise Value: crashed 209.98% in 2022, then surged 36.12% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$136.7 million in 2021, then fell by 28.6% to -$175.8 million in 2022, then grew by 17.79% to -$144.5 million in 2023, then fell by 6.45% to -$153.8 million in 2024, then tumbled by 42.04% to -$218.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$218.5 million in Q3 2025, -$189.9 million in Q2 2025, and -$185.0 million in Q1 2025.